Small Intestine Cancer - Pipeline Review, Q3 2011

Global Markets Direct, July 2011, Pages: 57

Small Intestine Cancer - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Small Intestine Cancer - Pipeline Review, Q3 2011', provides an overview of the Small Intestine Cancer therapeutic pipeline. This report provides information on the therapeutic development for Small Intestine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Small Intestine Cancer. 'Small Intestine Cancer - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Small Intestine Cancer.
- A review of the Small Intestine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Small Intestine Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Small Intestine Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Small Intestine Cancer pipeline depth and focus of Small Intestine Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Small Intestine Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Small Intestine Cancer
Small Intestine Cancer Therapeutics under Development by Companies
Small Intestine Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Small Intestine Cancer Therapeutics - Products under Development by Companies
Small Intestine Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Small Intestine Cancer Therapeutics Development
Amgen Inc.
Small Intestine Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG-479 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pyroxamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXD101 + 17-N-Allylamino-17-Demethoxygeldanamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD0473 + Pegylated Liposomal Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath + CHOP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMD 121974 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Gemcitabine Hydrochloride + Leucovorin Calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ganciclovir + Arginine Butyrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ursodeoxycholic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Tanespimycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Recombinant Alpha-2a-Interferon + Hydroxyurea + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Cyclosporine + Allogeneic Lymphocytes + Peripheral Blood Stem Cell Transplantation + Allogeneic Hematopoietic Stem Cell Transplantation + Total Body Irradiation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Oxaliplatin + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mFOLFOX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegylated liposomal doxorubicin hydrochloride + picoplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mFOLFOX6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Intestine Cancer Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Small Intestine Cancer, Q3 2011
Products under Development for Small Intestine Cancer – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Amgen Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Small Intestine Cancer Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Small Intestine Cancer, Q3 2011
Products under Development for Small Intestine Cancer – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Customers who bought this item also bought

• Lip Cancer - Pipeline Review, H2 2012
• Metastatic Prostate Cancer - Pipeline Review, H2 2012
• Pediatric Cancer - Pipeline Review, H2 2012
• Cancer Cachexia - Pipeline Review, H2 2012
• Oral Cancer - Pipeline Review, H2 2012
• Anaplastic Thyroid Cancer - Pipeline Review, H2 2012
• Oral Cavity (Mouth) Cancer - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2012
• Nausea - Pipeline Review, H2 2012